Deal gives poorer nations access to HIV prevention

A new deal grants lower-income countries access to the HIV prevention drug lenacapavir, a "game-changing" development, according to the Global Fund. The agreement between Gilead and the Global Fund will allow low- and middle-income countries to procure lenacapavir, a long-acting injectable drug. This marks the first time an HIV prevention product will be available in these countries simultaneously with high-income nations. Lenacapavir, requiring only two injections per year, has shown over 99.9% effectiveness in preventing HIV transmission. The Global Fund aims to reach two million people with the drug, with initial shipments planned for later this year.